| OBATOCLAX | Small molecule | lung cancer | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | primary myelofibrosis | Apoptosis regulator Bcl-W inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | small cell lung carcinoma | Apoptosis regulator Bcl-W inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| NAVITOCLAX | Small molecule | acute lymphoblastic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OBATOCLAX | Small molecule | lymphoid neoplasm | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | small cell lung carcinoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | prolymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | myeloproliferative disorder | Apoptosis regulator Bcl-W inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVITOCLAX | Small molecule | lymphoid neoplasm | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | Mantle cell lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | acute lymphoblastic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| OBATOCLAX | Small molecule | multiple myeloma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | neoplasm | Apoptosis regulator Bcl-W inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NAVITOCLAX | Small molecule | acute lymphoblastic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | metastatic melanoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX | Small molecule | acute myeloid leukemia | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | Hodgkins lymphoma | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | ovarian cancer | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | follicular lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX | Small molecule | Mantle cell lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | follicular lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX | Small molecule | Hodgkins lymphoma | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | myelodysplastic syndrome | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | small cell lung carcinoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| NAVITOCLAX | Small molecule | primary myelofibrosis | Apoptosis regulator Bcl-W inhibitor | 3.0 | Recruiting | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | myelofibrosis | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | Mantle cell lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | small cell lung carcinoma | Apoptosis regulator Bcl-W inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | prolymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | metastatic melanoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | primary myelofibrosis | Apoptosis regulator Bcl-W inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | follicular lymphoma | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | prostate cancer | Apoptosis regulator Bcl-W inhibitor | 2.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NAVITOCLAX | Small molecule | cancer | Apoptosis regulator Bcl-W inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OBATOCLAX | Small molecule | follicular lymphoma | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | small cell lung carcinoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | multiple myeloma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | non-small cell lung carcinoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| OBATOCLAX | Small molecule | small cell lung carcinoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | Mantle cell lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | acute myeloid leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVITOCLAX | Small molecule | myelodysplastic syndrome | Apoptosis regulator Bcl-W inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| NAVITOCLAX | Small molecule | primary myelofibrosis | Apoptosis regulator Bcl-W inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | lung cancer | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | myelodysplastic syndrome | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | lymphoid neoplasm | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | myelofibrosis | Apoptosis regulator Bcl-W inhibitor | 2.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | neoplasm | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVITOCLAX | Small molecule | primary myelofibrosis | Apoptosis regulator Bcl-W inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| NAVITOCLAX | Small molecule | lymphoblastic lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |
| OBATOCLAX | Small molecule | diffuse large B-cell lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVITOCLAX | Small molecule | diffuse large B-cell lymphoma | Apoptosis regulator Bcl-W inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| OBATOCLAX MESYLATE | Small molecule | diffuse large B-cell lymphoma | Apoptosis regulator Bcl-W inhibitor | 1.0 | Terminated | ClinicalTrials |
| OBATOCLAX | Small molecule | chronic lymphocytic leukemia | Apoptosis regulator Bcl-W inhibitor | 1.0 | Completed | ClinicalTrials |